Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.

Abstract

To characterize the lipid and lipoprotein abnormalities in patients with diabetes mellitus and evaluate the risks and benefits of marketed pharmacologic therapies, a MEDLINE search of the National Library of Medicine data base was performed of studies published from January 1966 to March 1994. Clinical trials assessing effects on lipids and lipoproteins, and adverse effects of marketed lipid-lowering agents were extracted. Reviews and other relevant articles were included if they provided information regarding lipid and lipoprotein metabolism or guidelines on the treatment of dyslipidemias in patients with diabetes mellitus. An extensive review of clofibrate was not included. The most common dyslipidemia in patients with poorly controlled insulin-dependent diabetes mellitus (IDDM) is combined elevated triglyceride and cholesterol levels, with reduced high-density lipoprotein (HDL) cholesterol (mixed hyperlipidemia). Hypertriglyceridemia combined with a reduced HDL cholesterol is the most common dyslipidemia in patients with noninsulin-dependent diabetes mellitus, but essentially any pattern of dyslipidemia may be present. Small and dense low-density lipoprotein (LDL), glycosylation of lipoproteins, and increased oxidized lipoproteins may be present in patients with diabetes mellitus; all contribute to accelerated atherosclerotic cardiovascular disease. Insulin therapy generally corrects quantitative lipid abnormalities in patients with IDDM, so drug treatment is seldom indicated. Diet, exercise, and insulin or oral sulfonylureas will improve hypertriglyceridemia and low HDL concentrations, but do not always return them to normal. Drug therapy is indicated when nonpharmacologic measures are inadequate. It is administered based on the effects of each agent on lipids and lipoproteins, patient age, adverse effect profile, patient tolerability, and drug-disease and drug-drug interactions. A fibric acid derivative is the drug of choice for marked hypertriglyceridemia in patients with diabetes mellitus. Niacin can worsen glycemic control, but it may be required in severe hypertriglyceridemia, hypercholesterolemia, or mixed hyperlipidemia. Bile-acid binding resins may accentuate hypertriglyceridemia but may be useful in selected patients with marked hypercholesterolemia and normal triglycerides. Hydroxymethylglutaryl coenzyme A reduced inhibitors are preferred in patients with elevated LDL cholesterol and mild hypertriglyceridemia. Patients with marked lipid abnormalities or mixed hyperlipidemias may require carefully dosed combinations of lipid-lowering drugs.

• Authors: J C Oki
• Journal: Pharmacotherapy (Pharmacotherapy) 1995 May-Jun Vol. 15 Issue 3 Pg. 317-37 ISSN: 0277-0008 [Print] United States
• PMID: 7667166 (Publication Type: Journal Article, Review)

Chemical References

• Anticholesteremic Agents
• Lipids
• Lipoproteins
• Lipoproteins, LDL
• Lipoproteins, VLDL
• Triglycerides
• Cholesterol

Topics

• Adult
• Anticholesteremic Agents (therapeutic use)
• Behavior Therapy
• Cholesterol (blood)
• Diabetes Complications
• Diabetes Mellitus (metabolism, therapy)
• Female
• Humans
• Hyperlipidemias (complications, metabolism, therapy)
• Lipids (blood)
• Lipoproteins (blood)
• Lipoproteins, LDL (blood)
• Lipoproteins, VLDL (blood)
• Male
• Middle Aged
• Risk Factors
• Triglycerides (blood)